Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush
Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued to investors on Monday,RTT News reports. They presently have a $33.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 278.01% from the stock’s previous close. Separately, Piper Sandler […]
